Teleshuttle Technologies

Teleshuttle is a biotechnology company founded by Dr. Richard J. Ablin, the scientist credited with the discovery of Prostate-Specific Antigen (PSA). The company was established to develop and commercialize the "Teleshuttle" platform, a proprietary targeted drug delivery system designed to transport therapeutic agents directly to cancer cells while sparing healthy tissue. This technology utilized specific ligands or antibodies as carriers to deliver payloads, such as cytotoxic drugs or toxins, specifically to cells expressing tumor-associated markers. The primary focus of the company's research was the treatment of prostate cancer, aiming to enhance therapeutic indices and minimize systemic side effects through precise molecular targeting.